Rayner announced the launch of Optiesis Cohesive, a proprietary new ophthalmic viscosurgical device (OVD), marking an expansion of its OVD portfolio and surgical product offering.
According to the company, Optiesis Cohesive is formulated with a high-molecular-weight formulation designed to deliver strong viscosity and cohesiveness. The product contains 1.1 ml of sodium hyaluronate at a concentration of 2.9%, a formulation intended to provide enhanced space maintenance during cataract and other anterior segment procedures.
Rayner highlighted two key benefits of the new device: a larger volume than comparable products and room-temperature storage, eliminating the need for refrigeration and potentially simplifying inventory management for surgical centers.
The introduction of Optiesis Cohesive is accompanied by a broader rebranding of Rayner’s OVD family. The portfolio now includes:
- Optiesis Cohesive – designed for strong space creation and stable anterior chamber maintenance with easy removal at the end of surgery
- Optiesis Dispersive – intended to provide high retention and effective endothelial cell protection
- Optiesis Adaptive PRO – a versatile, high-viscosity OVD containing 4% sorbitol, designed to combine space maintenance in the anterior chamber with endothelial cell protection during phacoemulsification and trauma cases
Ophteis Cohesive is CE marked and is now available in applicable markets, with further regions to follow subject to regulatory approval.
